In the United States, human papillomavirus (HPV) and Papanicolaou (Pap) testing (cotesting) for cervical screening in women ages 30 to 65 years is the preferred strategy, and cytology alone is acceptable. Recently, a proprietary automated test for identifying high-risk HPV types for primary cervical screening was approved by the US Food and Drug Administration. The objective of the current study was to document extensive cervical screening among these screening options. METHODS: To investigate the sensitivity of various testing options for biopsy-proven cervical intraepithelial neoplasia grade 3 or worse (CIN3) and cancer, the authors reviewed 256,648 deidentified results from women ages 30 to 65 years at the time of cotest who had a cervical biopsy specimen obtained within 1 year of the cotest. 
INTRODUCTION
In the United States, concurrent human papillomavirus (HPV) and Papanicolaou (Pap) testing (cotesting) is recommended for cervical cancer screening among women ages 30 to 65 years. [1] [2] [3] These guidelines were developed based on the success of Pap test screening in decreasing cervical cancer incidence and mortality in the United States over the last several decades. In addition, guideline development relied on the success of adding US Food and Drug Administration (FDA)-approved HPV testing to routine cervical screening with a Pap test in women aged 30 years, which further decreased the incidence of cervical intraepithelial neoplasia grade 3 or worse (CIN3) cervical biopsy results. [1] [2] [3] [4] [5] [6] [7] Recent studies have argued that HPV-only screening may be more effective than Pap-only screening for cervical precancer and cancer at screening intervals 3 years. [4] [5] [6] [7] [8] [9] [10] However, those prospective trials were performed among selected populations in well defined, controlled circumstances and usually compared HPV-only testing with Pap-only testing rather than guideline-recommended cotesting. 6, 9 Two publications from 1 US longitudinal study in a clinical practice setting attempted to estimate results from HPV-only screening compared with cotesting. Those reports indicated that cotesting afforded better protection from developing CIN3 and cancer when performed at similar screening intervals compared with HPV-only testing. 10, 11 In April 2014, the cobas HPV test (Roche Molecular Systems, Inc, Pleasanton, Calif) was approved by the FDA for primary cervical cancer screening in women aged 25 years. 12 To more fully investigate the potential benefits of HPV-only screening, HPV-only test results must be compared with cotest results in the detection and prevention of invasive cervical cancer in real-world clinical practice with clinical populations that are not preselected. Furthermore, to determine the impact of changes to a screening program that has decreased the incidence of cervical cancer to 7.0 per 100,000 women per year (2011), 13 large sample numbers are needed to establish cancer risks for each cytologic abnormality and HPV test result, particularly for women who are negative for HPV and/or cytology testing.
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HPV-only primary screening for cervical cancer presents many challenges for clinicians. Questions arise regarding its effectiveness, its long-term risk, and when it is the best option for a particular patient.
14 Clinicians had similar questions when cotesting was first recommended for women aged 30 years in 2006. Since then, the adoption of cotesting has steadily increased, with approximately 50% of physicians cotesting women aged 30 years, but it still is not done at the recommended level. 15, 16 In addition, as we seek to further prevent cervical cancer, we must be mindful to maximize disease detection while minimizing the harms associated with screening and overtreatment. 17, 18 The objective of this Quest Diagnostics Health Trends study was to provide a real-world, retrospective comparison between 3 screening approaches for cervical cancer (Pap-only testing, HPV-only testing, and Pap/ HPV cotesting). With more than 250,000 samples, we sought to compare the 3 screening approaches based on cervical biopsy results, including squamous cell carcinoma, adenocarcinoma, and cervical intraepithelial neoplasia (CIN) grade 3 or greater (CIN3). Our objective was to provide practical clinical data to inform the discussion regarding the choice of an appropriate cervical cancer screening methodology and to help determine the most effective screening method for the early detection and appropriate treatment of cervical cancer.
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MATERIALS AND METHODS
Quest Diagnostics (Madison, NJ) has more than 145 million patient encounters each year across the United States. For this study, we extracted testing data from women as described below. All data were deidentified before analysis. This study was determined to be exempt by the Western Institutional Review Board.
Woman ages 30 to 65 years at the time of cotesting were included in the study if they had a cervical cancer biopsy Histologic findings at biopsy were classified (in order of increasing severity) as no lesion found, CIN1, CIN2, CIN3, adenocarcinoma in situ, squamous cell carcinoma, or adenocarcinoma. All cervical biopsy results were further reviewed for confirmation of findings and for language and were excluded when information was not complete. Twenty-four biopsies and patient results were removed from the final data set because they were not considered to be primary cervical disease. Any misclassified CIN1/CIN2 specimens, lymphomas, endometrial adenocarcinomas, metastatic adenocarcinomas, melanomas, or malignancies were removed.
We calculated the distribution of cervical biopsy results for all women ages 30 to 65 years who had a biopsy preceded by a cotesting result during our study period. In addition, we calculated the sensitivity, specificity, positive predictive value, and negative predictive value for the tests within the study population. Statistical comparisons were made using the Pearson chi-square test to assess the difference between proportions. All statistical analyses were performed with the SAS statistical software package (SAS version 9.4; SAS Institute Inc, Cary, NC).
RESULTS
We evaluated 256,648 samples from women ages 30 to 65 years who had a cotest and a cervical biopsy within 1 year of each other at Quest Diagnostics. In this population, 74 
DISCUSSION
The primary objective of this study of cervical cancer screening and cervical biopsy results from more than 250,000 women was to provide a systematic and realworld comparison of 3 screening options for cervical cancer detection in women ages 30 to 65 years: the Pap-only test, the HPV-only test, and the Pap/HPV cotest. We examined the results from all cervical biopsies that were performed within 1 year of a cotest in women ages 30 to 65 years and observed that cotesting identified CIN3 cervical biopsy results more frequently than Pap-only or HPV-only testing (98.8% vs 91.3% vs 94%, for cotesting, Pap-only testing, and HPV-only testing, respectively). The higher sensitivity associated with cotesting indicates that it identifies more women who have CIN3 cervical biopsy results compared with Pap-only or HPV-only testing. The studies by both Katki et al and Gage et al demonstrated Abbreviations: CI, confidence interval; HPV, human papillomavirus; NPV, negative predictive value; Pap, Papanicolaou; PPV, positive predictive value. a Of 256,648 women, 4090 (1.6%) had cervical intraepithelial neoplasia grade 3 or more severe biopsy results. The distributions of positive and negative screening results by biopsy finding are summarized in Table 1 .
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complementary findings, indicating that a negative cotest was more protective against CIN3 for up to 4 years compared with HPV-only or Pap-only testing. 8, 10, 11 In the current study, cotesting identified more CIN3 cervical biopsy results in women who tested negative for HPV within 1 year before cervical biopsy, consistent with other reports.
11, 13 The current results suggest that 6% of women who have CIN3 cervical biopsy results might receive a false-negative screening result if they were tested with HPV only. Because most CIN3 does not progress to cancer, 21 it is of more concern that approximately 19% of women with biopsy-documented cancer in our study tested negative for HPV. The largest available cervical cancer series to date have documented similar patterns, reporting negative HC2 HPV results in approximately 10% of women with biopsy-confirmed cancer. [22] [23] [24] [25] This is probably because of lower viral loads below the test cutoff point, older age (as demonstrated in our data), and the presence of adenocarcinoma. [26] [27] [28] However, HPV-negative cancers in older patients may reflect an increased time before cancer diagnosis, the issue of true-negative or false-negative results, a smaller lesion size, or lower viral titers during earlier periods. 26, 27 Finally, qualitative and/or quantitative changes that may occur during some persistent high-risk HPV infections might be sufficient to cause persistently high-risk HPV-infected patients to have negative test results for HPV. 26, 27 Our current findings are also consistent with other reports in which a negative baseline HPV-test result occurred in 16% to 42% of women with cervical cancer who were diagnosed from 2.5 to 8 years later after a cotest. 7, 10, 27 Extrapolating our results to the US population suggests that nearly 2400 women with cervical cancer (of the 12,360 women who are estimated by the American Cancer Society to be diagnosed with cervical cancer each year) could be misdiagnosed annually if they were screened with HPV-only testing. 29 It is particularly striking that 26.6%
of women who were diagnosed with adenocarcinoma in our study population were HPV negative. A recent, large, worldwide analysis of 682 paraffin-embedded cervical adenocarcinoma specimens reported polymerase chain reaction-detectible HPV DNA in only 428 of 682 (62.8%) cervical tumors, 30 similarly suggesting significant limitations for HPV testing in the detection of increasingly prevalent cervical glandular neoplasms.
There are limitations to this study. We cannot confirm that the cervical biopsy results were from women who did not have an intervening screening test or treatment with a different provider during the study period. Also, because we investigated the screening results of women who underwent biopsies, we were unable to draw conclusions based on the overall population of women who were screened for cervical cancer. Approximately 75% of all positive cotests performed at Quest Diagnostics did not have follow-up biopsies that we could identify.
This study used the Qiagen HC2 assay for detection of high-risk HPV. A recent interim clinical guidance report has now emphasized that, between the 4 available HPV assays, assumptions should not be made that the assays are comparable and that an FDA-approved test should not be used by clinicians without a specific indication for primary HPV screening. 31 Therefore, estimates of possible levels of cervical cancer protection based on HC2 data (theoretically used in a non-FDA-approved manner) may not be transferrable to primary screening outcomes using the Roche cobas high-risk HPV testing algorithm (Roche Molecular Systems, Inc). Currently, almost all risk estimates of possible protection from developing cervical cancer with primary HPV testing rely mainly on HC2 testing data. 7, 10, 11 Finally, we reviewed these data to make sure there were no differences between SurePath and ThinPrep testing in CIN3 results for HPV-only or Pap-only testing by age and negative results, and no significant differences were observed. Additional strengths of this study include its real-world population of more than 250,000 women and more than 500 cervical cancers and its unselected clinical results rather than those from a controlled study population.
Conclusion
In this Quest Diagnostics Health Trends study, HPV/Pap cotesting identified more women whose cervical biopsy result revealed a finding of CIN3 than HPV-only testing when offered as a primary screening test for cervical cancer. These data highlight that up to 19% of women with cancer may be falsely reassured of a negative screening result when they are screened using HPV-only testing.
The results of our current study, as well as limitations of the study that led to FDA approval of an HPV-only primary test, including abnormally low cytology performance, lack of a cotesting comparator algorithm, the inclusion of women aged <30 years, requiring up to 3 follow-up visits, and no long-term follow-up, all raise
Original Article concerns regarding the suitability of HPV-only testing as a primary cervical cancer screen. 32, 33 Because early detection and treatment of cervical cancer are critical to the overall health of women, it is important that the best and most sensitive diagnostic tools for cancer detection be identified and made available to all women. Our data support cotesting in women ages 30 to 65 years as the most effective screening test for detecting cervical cancer.
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